EPIC-B: cemiplimab as first-line therapy in advanced penile cancer

Описание: Amarnath Challapalli, MBBS, MD, MRCP, FRCR, PhD, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK, discusses the Phase II EPIC-B trial (95561634) of first-line treatment cemiplimab in patients with locally advanced or metastatic penile squamous cell carcinoma, which has limited therapeutic options beyond chemotherapy. A modest 12-week clinical benefit rate and objective response rate were reported. Cemiplimab was also generally tolerable, making cemiplimab a viable option for chemotherapy-ineligible patients. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.